[Lenvatinib for iodine-refractory differentiated thyroid cancer]

Salvi R, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001563
Original Title: Lenvatinib en cáncer de tiroides diferenciado iodo refractario
Authors' recommendations: High-quality evidence shows that lenvatinib increases progression–free survival and objective response rate versus placebo in patients with differentiated thyroid cancer refractory to iodine therapy. Very low-quality evidence does not allow to draw conclusions regarding the comparison between lenvatinib and sorafenib in patients with iodine-refractory differentiated thyroid cancer. It is to note that the comparison between both treatments was performed indirectly, only with two randomized trials which included patient populations with different prognoses, and the anti-tumor clinical response was assessed using different versions of RECIST Criteria, among other differences. There is consensus among the clinical practice guidelines on recommending levantinib as first line therapy for patients with iodine-refractory differentiated thyroid cancer. It is covered in high-income countries. Canada and United Kingdom consider that lenvatinib is not cost-effective for treating idodine-refractory advanced thyroid cancer; however, they recommend its inclusion since this disease is not very common, with few therapeutic alternatives and, although lenvatinib benefit on overall survival is not very clear, it provides benefits on objective response rate with symptom control.
Project Status: Completed
Year Published: 2019
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Thyroid Neoplasms
  • Iodine Radioisotopes
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinolines
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.